Bernstein J E, Medenica M, Soltani K, Solomon A, Lorincz A L
Arch Dermatol. 1980 Sep;116(9):1041-44.
Malignant melanoma derives from melanocytic cells that possess the special biochemical pathway for the conversion of levodopa to melanin. Levodopa is widely employed in the treatment of Parkinson's disease, and several patients receiving levodopa have been observed to have acquired melanomas, raising concern about a possible relationship between this drug and the tumor. We encountered a 74-year-old woman in whom three distinct primary melanomas developed after she had been receiving long-term therapy with levodopa and a decarboxylase inhibitor. These lesions could be distinguished histologically from epidermotropic metastatic melanoma. Although the association between levodopa and melanoma is tenuous, careful monitoring of pigmentary changes in patients receiving levodopa is advised.
恶性黑色素瘤起源于黑素细胞，黑素细胞拥有将左旋多巴转化为黑色素的特殊生化途径。左旋多巴广泛用于治疗帕金森病，已有数例接受左旋多巴治疗的患者被观察到罹患黑色素瘤，这引发了人们对该药物与肿瘤之间可能存在关联的担忧。我们接诊了一名74岁女性，她在长期接受左旋多巴和一种脱羧酶抑制剂治疗后出现了3处不同的原发性黑色素瘤。这些病变在组织学上可与亲表皮转移性黑色素瘤相区分。尽管左旋多巴与黑色素瘤之间的关联尚不明确，但建议对接受左旋多巴治疗的患者仔细监测色素变化。
